Looks like partner plans or a possible strategic alliance is in the works. Very early discussions but the truth remains that they are least "talking" to external partners. I'm still not sure what Mills was doing over there for all that time? Young CEO is on target, ambitious and clearly focused - just taking 2-3 years longer than anyone wants. Its still progress.
Some good news guys. anyone knows how it is supposed to affect the company's sales?
Stxs could possible make progress , the new Ceo stating that company Robotic technology could b leaverage in other Medical applications .will listen for any questions or updates in coming C.C. about exploiting Robotic technology ..It could be the game changer for what now appears to be dying company ..IMO
Here's to at least two new systems sales in the most recent quarter and the beginnings of a new backlog. Need some momentum! Come on...papa needs shoes, baby needs clothes
What is anyone’s opinion on this one? I owned it and sold around $1.00 a couple years ago. Sales aren’t great but they are selling a couple systems at least. The research side seems promising.
Job well done over there . So well in fact they are all patting themselves on the back and handing out option awards. Pinch me.
yes, slow growth vs no growth, still not as good as strong growth will good products. Looking to see if they introduce the upgrade in Europe, then bring it over to US. Will Wait to see if this new CEO is blowing smoke out his backside. He laid out how he expects the next 2 qtrs to go. If he can not keep his word, not worth owning.
Guidance is safe....can only be improved....reason being that they have the two systems Fishel/Ceo was mentioning already in the backlog...booked and already paid for (prepaid) in Q4 (=Mills)...as such they will not be cash relevant this year....
lets see what Fishel will add to that equation...
Shareholder value is junk vs peers....reason, imo
mgment does not care at all....when pos mills left he was happy to have achieved the "deleverage objective" after 3 years the public was not aware of (sse his remarks on q3 16)....the factual consequence
1. zero insti in anymore/no interest 2. zero funds in anymore/no interest 3. zero analyst covering it/no interest
in short...deengaging with the investment community worked fine for them....
now, if new mgment changes that back to reeengaging the investment community it will be golden....however, it took mills more than 3 years to destruct the company...as such it will take time to recover because it is a credibility issue in the first place...
at least there is guidance (which needs to be upped on a regular basis)...also there is the automation path specified and the stop VT clinical...seems easy
OK , Give the new CEO a brownie point for doing one thing he said he would do. Now how will this help them financially moving forward
Where is the Masimo effect? They throw in $24 million and put new CEO in. When do they get this thing rolling?
Growing slow on purpose.
Been thinking about this lately. Consider the fact that they have no competitors. Why? Because the market for robotic ablations is slow, stale and fading. But then think about the other way - if they had something useful then everyone would want one, of course they could not make them fast enough, and then larger competitors would enter the space.
My theory is that they have planned this all along and still want another 2-3 years to exist in the dark. Then, one day, they are going to flip the switch and let the cat out of the bag about all they had been planning for all these years.
Its going to be dead money for quite some time unless boy wonder decides he wants to share the news a little bit.
Also anyone know what happened to Mills? I could see that guy retiring at a golf course or something, telling old jokes at the bar and then maybe getting drunk on happy hour?
What caused the sudden drop shortly before trading closed ?
hey, i am considering buying some shares of STXS - looks like the guys from Dafna Capital took over... they are professional investors. any thoughts?
Any discussion on the latest earning call. Sounds like they want to do well and that they believe they have the right product. The call was great until questions were asked and then my optimism was drowned by lousy answers to simple, basic questions. What a shame.
Just listened to call. Did they say they have 25 sales reps worldwide and have visibility on ONE new system sale for all of 2017? Should it be me or someone else who calls them and lets them know they don't need a sales force? They need farmers and account managers to only act on current sites.
BIG DEAL TO ACQUIRE UP TO 9 MARKETED PRODUCTS IMMINENT = 2000%++ UPSIDE POTENTIAL !!! AQSZF (MC $11 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .
Market Cap :US$ 11 Million Cash $4.1 Million << enough untill mid 2018 Price 0.18
File for CDN approval of Oxcarbazepine XR in 1H 2017
Additional Product Deals in 2017
Partnership for AQS1301 in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
Aequus has an expanding product pipeline of drugs in Canada. Revenues and cash flows are increasing and products produce a 50% margin, Edward Karr, Managing ...
Interesting momentum out there on renal denervations. Looking through the ongoing work (Symplicity Spyral, RADIANCE-HTN (NCT02649426) and REINFORCE (NCT02392351, n=100)) lots of new interest out there. What is encouraging is that back in 2011 Petr Neuzil, MD, PhD, Head of Cardiology and Director of the Cardiac Arrhythmia Service at the Na Homolce Hospital in Prague, Czech Republic used a Niobe to get this done and had 100% accuracy of ablations whereas the struggle even with say symplicity is that you have to "hope and pray" you are in the right area.
Double down on VT where they know <5% of all cases really need it. When are they going to start using this machine in other areas and actually think about growing their sweet spot? Cardio alone isn't going to cut it.
sick management these people only want pay check and bonus that all not really worried about the company and share holder fxxk that CEO